OBSTETRICAL EMERGENCIES Hemorrhage

PPH-**P**redict-**P**repare-**H**andle



Objectives

hemorrhag

Predict

Identify methods to predict the patient risk of PPH

Prepare

Recognize evidence based practices to be prepared for a PPH


Handle

Understand the Clinical management of PPH

Add disclosure

The Why

- Hemorrhage is a leading and most preventable cause of severe maternal morbidity and mortality (SMM)
- 1-3%- 10% of all births
- 12.1 of pregnancy related deaths
- Rates are increasing
- Leading cause of ICU admissions
- High rate of preventability
- Reducing the likelihood of harm related to Maternal Hemorrhage is now a Joint Commission Standard of care



PREDICT:

Definitions:

- Primary or Early: 1st 24h after birth
- Secondary or Late: 24h to 12 weeks post birth
- > 500-1000cc
- > 10 point drop in HCT or need for blood transfusion



Organization	Definition of PPH
World Health Organization ^[1]	 Blood loss ≥500 mL within 24 hours after birth. Severe PPH: Blood loss ≥1000 mL within the same time frame.
American College of Obstetricians and Gynecologists ^[2]	 Cumulative blood loss ≥1000 mL or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours after the birth process (includes intrapartum loss) regardless of route of delivery.
Royal College of Obstetricians and Gynaecologists ^[3]	 Minor PPH (500 to 1000 mL) and major PPH (>1000 mL). Subdivisions of major PPH include moderate (1001 to 2000 mL) or severe (>2000 mL).
International expert panel ^[4]	 Active bleeding >1000 mL within the 24 hours following birth that continues despite the use of initial measures, including first-line uterotonic agents and uterine massage.
Society of Obstetricians and Gynaecologists of Canada ^[5]	 Any amount of bleeding that threatens the patient's hemodynamic stability.
California Maternal Quality Care Collaborative ^[6]	 Stage 0: Every woman in labor/giving birth. Stage 1: Blood loss >500 mL after vaginal or >1000 mL after cesarean delivery; or change in vital signs >15% or heart rate ≥110 beats/minute, blood pressure ≤85/45 mmHg, O₂ saturation <95%. Stage 2: Continued bleeding with total blood loss <1500 mL. Stage 3: Total blood loss >1500 mL or >2 units packed red cells transfused; or unstable vital signs; or suspicion of disseminated intravascular coagulation.

1. References: World Health Organization. WHO recommendations for the prevention and treatment of postpartum hemorrhage. Geneva: World Health Organization; 2012. 2. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin Number 183, October 2017: Postpartum hemorrhage. Obstet Gynecol 2017; 130:e168. 3. Prevention and management of postpartum haemorrhage: Green-top guideline No. 52. BJOG 2017; 124:e106.

Abdul-Kadir R, McLintock C, Ducloy AS, et al. Evaluation and management of postpartum hemorrhage: Cnsensus from an international expert panel. Transfusion 2014; 54:1756.
 Leduc D, Senikas V, Lalonde AB, et al. Active management of the third stage of labour: Pevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can 2009; 31:980.
 CMQCC. <u>www.cmgcc.org/resources-tool-kits/toolkits/ob-hemorrhage-toolkit</u> (Accessed on May 17, 2017).

PREDICT: Risk Assessments



POSTPARTUM HEMORRHAGE (PPH) RISK ASSESSMENT TABLE • 1.1

CLINICIAN GUIDELINES:

11

factors as high risk.


· Prenatal risk assessment is beyond the scope of this document, however performing a prenatal hemorrhage risk assessment and planning is highly recommended. Early identification and management preparation for patients with special considerations such as placental previa/accreta, bleeding disorder, or those who decline blood

· Adjust blood bank orders based on the patient's most recent risk category. When a patient is identified to be at high risk for hemorrhage verify that the blood can be available on the unit within 30 minutes of a medical order.

- Plan appropriately for patient and facility factors that may affect how quickly the blood is delivered to the patient. For example,
- Patient issues: Pre-existing red cell antibody
- dealed as also blocked as solutioned a basis

					od supply and obtaining blood					
Autor Autor <th< th=""><th></th><th></th><th>RISK CATEGORY: ADMISSION</th><th></th><th></th><th></th><th></th><th></th><th></th><th>and the second se</th></th<>			RISK CATEGORY: ADMISSION							and the second se
<form> a browne programe browne program browne programe <t< td=""><td></td><td>Low Risk</td><td></td><td>High</td><td></td><td></td><td></td><td></td><td></td><td>vision 9/10/14</td></t<></form>		Low Risk		High						vision 9/10/14
<form></form>		No previous uterine incision	Induction of labor (with oxytocin) or Cervical ripening	Has 2 or More Medium R	P	renatal Assessme	nt & Planning			
		Singleton pregnancy	Multiple gestation	Active bleeding more that						
□ Not starting florided □ Reacting flor		≤4 Previous vaginal births	>4 Previous vaginal births	Suspected placenta accr			ucrose Protocol to reach o	-		
Bit No loom beeing degring during function Bit No loom beeing degring during function<			Prior cesarean birth or prior uterine incision	Placenta previa, low lying		<u> </u>				
If the full by a first days are in		No known bleeding disorder	Large uterine fibroids	Chown coagulopathy	record	labor, and postpartum. (At e		factors in lab	or:	itional nsk
Image: Image		No history of PPH	History of one previous PPH	History of more than one						
Image: Image			PPH (known or unknown etiology with possible	Hematocrit < 30 AND other AND Oth	specimen needed for confirmation) If prenatal or current antibody screen positive	Review Hemorrhage Prote High risk: Order Type & Crossmatch	2 units PRBCs	 Active blee Chorioamn Magnesium 	ding ionitis n sulfate treatment	
Image: And Image			Chorioamnionitis	Platelets <100,000/mm3	· ·		ocol			
			Fetal demise			Identify women who may declin		Treat multiple	e risk factors as High	h Risk
			Polyhydramnios						en postpartum for inc	ncreased
Call Call Call Cape and Hold) Call Data Type and Server () Call Data Type and Hold) Call Data Type and Hold) <t< td=""><td></td><td>Monitor patient fo</td><td></td><td>erventions as indicated.</td><td></td><td>Review Consent Form</td><td></td><td>-</td><td></td><td></td></t<>		Monitor patient fo		erventions as indicated.		Review Consent Form		-		
Absolution Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such as the Provider Clinical Nuess Speciality Didtly appropriate personnel such Nuess Nuess Nuess Nuess Nuess Nuess Nuess Nu	lood Bank	Clot Only (Type and Hold)	Obtain Type and Screen	Obtain Type and Cross (
Image: specified base of the specified o	lood bank rders as eeded if sk catego-		(OB MD/CNM), Anesthesia, Blood Bank, Charge Nurse, Clinical Nurse Specialist	(OB MD/CNM), Anesthesia Clinical Nurse Specialist	No previous uterine incision Singleton pregnancy ≤ 4 previous vaginal biths No known bleeding disorder No history of PPH	Prior cesarean birth(s) or uter Multiple gestation > 4 previous vaginal births Chorioamnionitis History of previous PPH Large uterine fibroids	Test, Pph Female, 35 y.o., 17/07/985 MRN: H001962075 Bed: GGO4A	Admission Asse Thage Admission As Admission As Admission As Admission As Admission As	sessment Presital Cgection PPH Risk - Admission Tme taken 1353 0 t	n an Postpartum Hemornhage Risk V192220 C
Year service Year service <td< td=""><td></td><td></td><td>ic and Neonatal Nurses. All rights reserved. Requests for permission s</td><td>appropriate level of care a high risk mother should be directed to permission</td><td>All Births – Prophylactic Oxytoc Active Management of Third Stage</td><td>1000 ml solution titrate infusion</td><td>POLST: None</td><td>Patient Profile Episodes Dating Overview & Plan Specimen Collection</td><td> Risk Category: Admissio Prior cesarean birth </td><td>ion</td></td<>			ic and Neonatal Nurses. All rights reserved. Requests for permission s	appropriate level of care a high risk mother should be directed to permission	All Births – Prophylactic Oxytoc Active Management of Third Stage	1000 ml solution titrate infusion	POLST: None	Patient Profile Episodes Dating Overview & Plan Specimen Collection	 Risk Category: Admissio Prior cesarean birth 	ion
No Strend Store No Strend Store <td>ide clinical</td> <td></td> <td>nical judgment.</td> <td></td> <td>Using formal methods, such as graduate Ongoing Evaluation of Vital Signs</td> <td>ed containers, visual compariso</td> <td>Not on File</td> <td>OR History PPH Risk</td> <td>vaginal births?</td> <td></td>	ide clinical		nical judgment.		Using formal methods, such as graduate Ongoing Evaluation of Vital Signs	ed containers, visual compariso	Not on File	OR History PPH Risk	vaginal births?	
MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT Device Otto Autoson MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT Device Otto Autoson MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT Device Otto Autoson MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT Device Otto Autoson MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC SUPPORT MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM MC NOCUNTER TOOM	ide clinical access the pendix 2. Re	e full 3 page Risk Assessment Tool, users n teprinted with permission from The AWHONN	nical judgment. nay visit www.AWHONN.org and enroll in the Postpartum Hemorrh N Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk asses	age online education course. Isment table 1.0. Available at: https	Using formal methods, such as graduate Ongoing Evaluation of Vital Signs If: Cumulative Blood Los Vital Signs > 15% change or HP > 110.	ed containers, visual compariso <u>ss > 500ml vaginal birth or ></u> BP ∡ 85/45, O2 sat < 95% <u>-4</u>	Not on File No blood loss documented PPH Risk Category: Low TRIAGE Cervical Exam: None	OB History PPH Risk PPH Risk Score Care Everywhere Med Surg History Allergies Existing LDAs Filed Documents	known bleeding disorder or coagulopathy? Patient or first disoree famble	
Derived Citro MD No P	ide clinical access the pendix 2. Re	e full 3 page Risk Assessment Tool, users n teprinted with permission from The AWHONN	nical judgment. nay visit www.AWHONN.org and enroll in the Postpartum Hemorrh N Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk asses	age online education course. Isment table 1.0. Available at: https	Using formal methods, such as graduate Ongoing Evaluation of Vital Signs If: Cumulative Blood Los Vital Signs > 15% change or HP > 110.	ed containers, visual compariso <u>ss > 500ml vaginal birth or ></u> BP ∡ 85/45, O2 sat < 95% <u>-4</u>	Not on File No blood loss documented PHP Rek Category Low TRAGE Cenvical Exam: None ROM: No data THIS PREGNANCY HIS GTIP0 GA: None	DB laistoy PPH Rak PPH Rak Score Care Everywhere Med Surg Hatory Aderges Existing LDAs Fied Documents Heath Care Apents Directives Patient Belongings Interprete Services	vaginal births? Known bleeding discrete or cospulopathy? Patient or first degree family members have a history of PPH? Induction or Augmentation of Augmentation of Cenvical Ripering?	History of one postpartum hemorihage History of more than one postpartum hemorin. First degree relative with history of postpartum hemorin. No Yee No
BP- Temp:- Temp:- Temp:	le clinical access the endix 2. Re	e full 3 page Risk Assessment Tool, users n teprinted with permission from The AWHONN	nical judgment. nay visit www.AWHONN.org and enroll in the Postpartum Hemorrh N Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk asses	age online education course. Isment table 1.0. Available at: https	Using formal methods, such as graduate Ongoing Evaluation of Vital Signs If: Cumulative Blood Los Vital Signs > 15% change or HP > 110.	ed containers, visual compariso <u>ss > 500ml vaginal birth or ></u> BP ∡ 85/45, O2 sat < 95% <u>-4</u>	Not on File No blood los documented PHY Eak Category Lew PHY Eak Category Lew Roth: No dat Roth: No dat His FREONNCY His GIPO GA: None Blood Type: None Lido Inxcourte: FODAY	OB Isotopy PPH Rak Score Care Everywhere Med Sorg History Akerges Eusting LDAs Field Documents Health Care Agents Directives Patent Beiongings Interpreter Services Team Birth Hudde Aconscork Assessment -	vaginal births? Known bleeding discrete or cospulopathy? Patient or first degree family members have a history of PPH? Induction or Augmentation of Augmentation of Cenvical Ripering?	Inc Ves No
Implicit Tempion Polyhydramicst Implicit NO ODERS TO ACMONITORI No NO WESSATT, LUST Jein No ACTIVE MEDS No ACTIVE MEDS NO ACTIVE MEDS Socie Ruit Conception to the Table Ta	le clinical access the endix 2. Re	e full 3 page Risk Assessment Tool, users n teprinted with permission from The AWHONN	nical judgment. nay visit www.AWHONN.org and enroll in the Postpartum Hemorrh N Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk asses	age online education course. Isment table 1.0. Available at: https	Using formal methods, such as graduate Ongoing Evaluation of Vital Signs If: Cumulative Blood Los Vital Signs > 15% change or HP > 110.	ed containers, visual compariso <u>ss > 500ml vaginal birth or ></u> BP ∡ 85/45, O2 sat < 95% <u>-4</u>	Not on Fie No blood loss documented FIF Bit Category Low TRACE Central Earn: None ROM No data THIS REQUENCY HIS CEROUNCY HIS CEROUNCY HIS CEROUNCY LOS ON OUT CAL NOO LOS ON OUT CAL NOO LOS ON OUT Desired CEROUNCY No active principal problem Desired CEROUNCH	Of Busing PPH Rak Sove PPH Rak Sove Eve Everywhere Wes Surg Islam Alerges Eustre Eustre EAA Field Documents Field	vapal beths? disara blending disardier de casgulagathy? Patient or first dispret family members have a history of Prot Augmentation of et Cencual Repending? Large sterme Brendin? Choringaminionts?	
NO OCERSIS TO ACCINONULDICE NO NILY RESULTS, LAST BMH NO ACTIVE MIDS NO ACTIV	e clinical ccess the ndix 2. Re	e full 3 page Risk Assessment Tool, users n teprinted with permission from The AWHONN	nical judgment. nay visit www.AWHONN.org and enroll in the Postpartum Hemorrh N Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk asses	age online education course. Isment table 1.0. Available at: https	Using formal methods, such as graduate Ongoing Evaluation of Vital Signs If: Cumulative Blood Los Vital Signs > 15% change or HP > 110.	ed containers, visual compariso <u>ss > 500ml vaginal birth or ></u> BP ∡ 85/45, O2 sat < 95% <u>-4</u>	Not on File I do Blood has doomwind Diff Eak Category, Lee TRACE Central Eak Trans None ROM No data THIS NEQUANY HIS CITO CAL None Blood Type None Blood Type None Blood Type None Decimal Cito MD Materding	Of Balance PPH Roat PPH Roat Score Care Desynthese Med Saray Hattor Alarges Exiting LDAs Field Documents Health Care Agents Directions Interpret Services Takent Servinghost Interpret Services Takent Servinghost Advessor Addissanter – Immunization Vala and Science. Field Utimer Achry Membranes	vapal beths? disara blending disardier de casgulagathy? Patient or first dispret family members have a history of Prot Augmentation of et Cencual Repending? Large sterme Brendin? Choringaminionts?	Initiation of one postpartum hemoritage
NO NEW RESULTS LAST JAH NO ACTIVE MIDS Physical statestime, NO ACTIVE MIDS Physical statestime, Physical statesti	e clinical ccess the ndix 2. Re	e full 3 page Risk Assessment Tool, users n teprinted with permission from The AWHONN	nical judgment. nay visit www.AWHONN.org and enroll in the Postpartum Hemorrh N Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk asses	age online education course. Isment table 1.0. Available at: https	Using formal methods, such as graduate Ongoing Evaluation of Vital Signs If: Cumulative Blood Los Vital Signs > 15% change or HP > 110.	ed containers, visual compariso <u>ss > 500ml vaginal birth or ></u> BP ∡ 85/45, O2 sat < 95% <u>-4</u>	Not on File Not an File Not blood has documented TH But Campury Low TRUE TH But Campury Low TRUE TH File Advancement The The The The Advancement The	Of Balance PPH Roat PPH Roat Score Care Desyndrome Med Surg Hollow Alarges Exiting Tourist Tendo Tourist Health Care Agents Directive Patent Biomongo Interprete Services Team Sim Mode Alargeson Assistance Team Sim Mode Alargeson Assistance Team Sim Mode Alargeson Assistance Team Sim Alargeson Team	vapad bertist dissue bleeding dissued are dis- calgulargathyt Patient or Krit dispret ranky members taken biological disease index of berti- biological dispression of Christian et dispression dispressi	
NO ACTIVE MIDS Phydosocal Socie Rek Phydosocal Socie Rek Phydosocal Socie Rek Phydosocal	e clinical access the endix 2. Re	e full 3 page Risk Assessment Tool, users n teprinted with permission from The AWHONN	nical judgment. nay visit www.AWHONN.org and enroll in the Postpartum Hemorrh N Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk asses	age online education course. Isment table 1.0. Available at: https	Using formal methods, such as graduate Ongoing Evaluation of Vital Signs If: Cumulative Blood Los Vital Signs > 15% change or HP > 110.	ed containers, visual compariso <u>ss > 500ml vaginal birth or ></u> BP ∡ 85/45, O2 sat < 95% <u>-4</u>	Not on File Not blood fore shournende THY Ruik Campoy Lee THY Ruik Campoy Lee Concil Learnin None ROM. No dra This HELGANNCY His CHP Ch There Lab INCONTEX TODY A schw principal problem Debiere Chto. MD RP.— Temp.— Temp.	Disator Phylic Rak Phylic Rak Score Cate EveryMere Med Surg Hatery Fared Documents Heath Care Agents Directives Directives Directives Directives Directives Directives Constructions Weight Directives Constructions Weight Directives Constructions Weight Directives Directives Directives Directives Constructions Weight Directives Di	vapad bertis? Grown bleeding dispeted party Patients of first dispeted party Induction et history of Pinits Induction et abor tenth orgicon of Cencial Reprintig Chorisamionetis? Chorisamionetis? Down Feal Demise?	
Com Disease hyp placetal	de clinical access the endix 2. Re	e full 3 page Risk Assessment Tool, users n teprinted with permission from The AWHONN	nical judgment. nay visit www.AWHONN.org and enroll in the Postpartum Hemorrh N Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk asses	age online education course. Isment table 1.0. Available at: https	Using formal methods, such as graduate Ongoing Evaluation of Vital Signs If: Cumulative Blood Los Vital Signs > 15% change or HP > 110.	ed containers, visual compariso <u>ss > 500ml vaginal birth or ></u> BP ∡ 85/45, O2 sat < 95% <u>-4</u>	Not on File Bo blood back documented EFF Raix Category, Low TRAC Convoid Same None ROM No das Test REGAUNY Hic G170 CA: None Exod Flype None Exod Flype None Desired Chas. MD Desired	Distorte Phys Rok Score Carls Everyhein Kask Score Carls Everyhein Kasker Schwarz Fried Boomens Heath Carls Agents Deschwa Heath Carls Agents Heath Carls Agents Deschwa Heath Carls Agents Heath Carls Agent Heath Carls Agents Heath Carls Agent	vapana bertis? Grown bleeding disorder of Knt darger fangt darger fangt history of Parts history	Two No
	ide clinical access the pendix 2. Re	e full 3 page Risk Assessment Tool, users n teprinted with permission from The AWHONN	nical judgment. nay visit www.AWHONN.org and enroll in the Postpartum Hemorrh N Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk asses	age online education course. Isment table 1.0. Available at: https	Using formal methods, such as graduate Ongoing Evaluation of Vital Signs If: Cumulative Blood Los Vital Signs > 15% change or HP > 110.	ed containers, visual compariso <u>ss > 500ml vaginal birth or ></u> BP ∡ 85/45, O2 sat < 95% <u>-4</u>	Not on File Hot on File EVI PEAK Company, Low INFAC EVI PEAK Company, Low EVIENT EXECUTION EVIENT	Difference Phylicites Score Carle Complete Med Social Score Carle Complete Med Social Score Patert Beingson Interpret Services Patert Beingson Interpret Services Patert Beingson Methods Scoren- Heinnucklone Umma Achieve Umma Achieve Mentones General Exam Beings Score Umason Heide Taberton- Discher Score Matter Score	vapana bertis? Group bleeding disorder of Krit degree and yet history of Party history of Party	Events accreta Placenta percenta Into Pro

PREDICT: Identify Patients at Risk



Etiology of Postpartum Hemorrhage

PREPARE to prevent: Active Management of the 3rd stage

- Oxytocin IVPB or IM with delivery of anterior shoulder or prior to placenta infant or placenta
- Cord clamping not delayed beyond 2 min
- Vigorous fundal massage (at least 15 sec) after placenta
- Controlled cord traction
- Saves blood loss at delivery



PREPARE with Risk Factors

- QBL 1G=1ml
- Confirm T & S done
- Confirm status of blood availability
- 2nd IV
 - Confirm blood availability
 - Have uterotonics readily available





PREPARE: Quantify Blood Loss



EBL vs QBL







•

PREPARE:

Policies and practices

Algorithm for identification and treatment

- Peopleresponse team, roles & responsibilities
- ✓ Equipment-
- ✓ Drugs
- ✓ Drills




Ma	ssive Transfusion Key	y Steps & Transfusion Guidelines (1-2022)	
BloodworksNW MD O	n-Call for transfusion	consultation: 206-292-6525 (option #3)	7) Transf
	1) Ongoin	g bleeding with blood loss >1500 mL or	Equipr
When to MTP in OB?	2) Hernod	lynamic instability or Suspicion of DIC	8) Pick-
	3) 2 Units	RBCs given, bleeding continues and unstable	Pack
1) Call x123 to activa	te CODE MTP		
2) Call Overlake Bloc	d Bank x 5084	1 Massive Transfusion Pack	Runner
·		Massive transtusion Pack	Mult
•	*Charge RN or		re
	Circulator in		
	main OR	180 do do do do do	9) Goa
"Only one contact person commu	nicates with Blood Ban		Core temp gr pH greater th
Give Contact Name, Cor	ntact information	1 Cryo Pool	Transfuse (1:
Patient Name, DOB, MRN	and MD Orderin	B 1 Platelet	
"Massive Transf	usion Pack'	Adult dose	11) Con
			Pitocin/Oxyte Methergine:
		Take 20+ ADT Labels Pick Up 1" Junits Uncrossmatched	Hemabate: IN
Immediately	9	Take 20+ ADT Labels Pick Up 1" Junits Uncrossmatched RBCs	Misoprostol: TXA: 1gram IV
Send Runner on Wa		1067 OMC	
Know what product & patient nar		Des, lare f. DOB 10/10/2075	13) Doc
		<10 minutes to dispense	14) Put a
4) Baseline Labs	Type & Screen	EXACT MATCH	Reports in
4) Duschine Cubs	2 pink top tubes	1. 2 RN's VERIFY: Pt Name, DOB, and MRN match EXACTLY	- 222
	1 X only	with armband	The second
		2. Specimen Collection DATE and TIME to specimen label	Titations
Epic	표표	and requisition	Land, Appendix A
5) Open Patient Chart	8 8	3. Phiebotomist ID on specimen label and requisition	accession of
Go to Order Sets	0 0	4. Second Verifier ID on req. Legibly PRINT first initial, last	105 HE
Order Massive		name	Transfusion
Transfusion Pack		(Serial Blood Draw Packets in MTP Kit)	for patients
Transfusion Pack	Baseline and	Hct/Hgb, Platelets (lavender top)	Hgb <7 g/dL
	Q 30 min	Magnesium	Direct Good
	Colored State	ABGs & Ionized Calcium (Resp Tx)	
	2 Large Bore IVs	No meds with blood components	INR 21.6
6) Access	Consider centra		Platelet
		blood	count < 100K
			Fibrinogen <150
			08 <u>pt</u> <300

7) Transfusion Equipment	Rapid Transfuser wi For RBCs and Plasma or	t h Fluid Warmer I <mark>ly</mark> – ok transfuse RBC-FFP same l	ine 🕺
8) Pick-up rest of Pack Runner returns to lab Multiple runs required	Take Chart Label Every Run Lipser, Gank Board Street		6 Plasma - 25 min dead type known - 10 min Crye - 13 min
9) Goals Core temp greater than 35°C pH greater than 7.3 Transfuse (1:1:1) = 6RBC:6Plasma	:1 adult dose platelets	10) Hemostasis Goals Symptomatic anemia subside INR is less than 1.7 Fibrinogen is greater than 10 Platelet count greater than 1	0 mg/dL
11) Concomitant OB Pitecin/Oxytocin: Continuous IV ii Methengine: IM q 2 - contrained Userplotty: IM q 15 - Asthma relat Misoprostol: one time oral, recta TXA: Sgram IVP (10ml of 100ml as	nfusion cation (C/I) HTN tive C/I consider antidienteal I or subling	 Review serial lab res Treat hyperkalemia, hypor and acidosis 	ults aicemia, hypomagnesemia
13) Document	Ordering MD Signs SUBJ Form (provided by lab)	REQUEST FOR BLOOD AND TRANSFUSING TESTING	Track Transfusions
14) Put all Transfusion Reports in Chart			Market State State Market State State Market State State Market State State Market Stat
Transfusion Guidelines Post Transfu for patients continuing to hemorrhage.	sion of Massive Transfusion Pack May need to order another MTP pack	Platelets a	and Cryo
Institute and a second	Het #3%	→ Keep at room t MTP GENER. Every 1 RBCS, give 1 Plasma Every 6 RBCs/6 Plasma, give 1 platele B Fibrinogen <300 or D0C suspected or carter	AL RATIO
Platelet 🔍 Gi	Plasma factors 12.5% ve 1 adult Platelets ¢ 20,000/pl to 30,000/ pl	Prevent Hypothermia Goal - Co	re temp over 35.0°C
	ve 1 adult dose Fibrinogen † 37 yoprecipitate	After MTP Pack transfus additional products	

HANDLE: Clinical Management

- Don't Deny or Delay
- Etiology-Identify and treat the cause (4 T's)
- Control hemorrhage
- Replace fluids/blood
- Monitor closely
- Anticipate going to the OR



HANDLE: Interventions for PPH

Get help- Name the emergency

HOB down, Fundal massage

Record VS, O2 sat every 5 minutes

Record QBL

Empty bladder

IV and 2nd IV

obtain labs (DIC panel) with IV start

□ Increase intravenous fluid

□ Increase or start oxytocin

Medications (uterotonics and TXA)

Confirm blood availability

□ Order 2 units RBCs if ongoing bleeding

□ I & O: hourly urine output

□ Maintain adequate ventilation

G Keep warm




DRUG	AMOUNT/ROUTE	RATE	CONTRAINDICATIONS
Oxytocin (^{Pitocin)} First- line agent	30 units in 500 mL IV fluid or 10 units IM (if no IV access)	125-999 ml/hr on pump (wide open if hemorrhage) Titrate to uterine tone	Potential fluid overload at total dose exceeding 80 units. DO NOT ADMINISTER IV push
Methergine (Methylergonovine) Second-line agent	0.2 mg (200mcg) IM Deltoid preferred route	Every 2-4 hours, up to 5 doses: If bleeding continues after one dose, move immediately to next agent	Contraindicated with HTN disorders including preeclampsia due to potential for sudden hypertension and CVA. DO NOT ADMINISTER IV
Hemabate (Carboprost) Third-line agent OR second-line agent after oxytocin if methergine is contraindicated	250 micrograms IM or intramyometrial	Every 15-90 minutes, up to 8 doses: If bleeding continues after third dose, move immediately to next intervention	Asthma is relative contraindication DO NOT ADMINISTER IV Combine (LOMOTIL) tablet 1-2 tab PO Q6H PRN Diarrhea, x24 hours to cover prostaglandin-related diarrhea
Misoprostol (Cytotec) Alternate to hemabate if contraindicated. If bleeding continues after one dose, move immediately to next intervention.	Tablet(s) 800 mcg SL (rapid action) 800-1000 mcg Rectally Do Not Use Lubricant (delayed absorption)	X1 dose If bleeding continues after one dose, move immediately to next intervention.	No contraindication- use only if Hemabate is contraindicated Side effects: Fever and Rigors Works most effectively when used with other medications listed in this table (synergistic action).
Tranexamic acid (TXA)	1 gram IVP Ideally within 3h of hemorrhage	Infused over 10 minutes, up to 2 doses If bleeding persists after 30 minutes may be repeated with provider order	Renal Failure, DIC, Subarachnoid Hemorrhage, Thrombus Caution: do not mix with blood, heparin or give through line with blood or solutions containing penicillin or ampicillin

HANDLE: Close Monitoring

Estimated Blood Loss (ml)	Heart Rate	Systolic Blood Pressure	Respiratory Rate	Signs and Symptoms
1000	Normal	Slight ↓	Normal	Palpitations, dizziness Normal urine output
1500	Over 100	Narrowed pulse pressure	20-30	Diaphoresis, Weakness Urine output 20-30 ml/hr
2000	Over 120	Narrowed pulse pressure	30-40 SOB	Restlessness, Pallor, Cool extremities Urine output 5-15 ml/hr
>2500	Over 140	Profound hypotension	over 40	Anuria, Altered consciousness

Hypotension is a LATE sign



HANDLE: To the OR

- If uterotonics and bedside interventions do not control the bleeding-
- Move to the OR
 - Consider D&C, intrauterine balloon, or other surgical intervention
 - Labs CBC and coag studies repeat every 30 minutes with ongoing bleeding
 - Repeat hemabate as often as every 15 mins
 - Order blood products- transfuse as clinically indicated



HANDLE: Treatment Options

- If retained placenta :D&C
- If trauma: visualize and repair
- If uterine atony: tamponade balloon, Jada, packing
- If needed, move to interventional radiology, hysterectomy
- If C/S: b-lynch suture, uterine artery ligation, tamponade balloon
- If vital signs are worse than estimated or measured blood loss: possible uterine rupture or broad ligament tear with internal bleeding; move to laparotomy

HANDLE

Be vigilant in appreciating:

- PPH RISK
 Assessment
- HR > 110
- QBL > 1000
- Blood Pressure ≤85/45 (>15% drop)
- Oxygen Saturation <95%
- Trust your gut
- Don't wait for labs to transfuse

"The clinical symptoms of blood loss (low blood pressure, fast pulse, pallor and sweating, signs of hypovolemia and impeding shock) are often the primary indicators for intervention. However, relying on the onset of such symptoms may lead to delayed intervention, resulting in increased morbidity and mortality."

B.S. Kodkany and R.J. Derman. Pitfalls in Assessing Blood Loss and Decision to Transfer



HANDLE: Transfusion Considerations

Correction of tissue hypo perfusion

• Volume replacement with crystalloid

Correction of hypothermia

- Use blood warmer
- Use patient warming device

Correction of anemia/coagulopathy

- Assess labs & signs/symptoms
- Labs may lag behind clinical signs
- Transfuse platelets and FFP as well as PRBCs



Blood products


Packed Red Blood Cells (PRBC)	Best first line product for blood loss 1 unit typically increases Hbg 1 g/dL If antibody positive, may take 1-24 hours for cross match
Plasma (FFP)	Active bleeding or risk of bleeding due to coagulation factor deficiency. After the first two units of PRBC's, early transfusion with plasma is correlated with improved survival from hemorrhage after trauma Highly desired if > 2 units PRBCs given Expect corrected aPTT, PT and INR Approx. 10-20 mins to thaw
Cryoprecipitate (CRYO)	Priority for women with Fibrinogen levels < 100 Use for DIC with low fibrinogen and don't need volume replacement Caution: 1 pool contains 5 units, each from a separate donor. Infection risk is proportionate to the number of donors. Patient typically receives 1-2 pools. Approx. 10-20 mins to thaw
Platelets (PLTS)	Priority for women with Platelets < 50,000, with ongoing bleeding Apheresis unit provides 10,000-60,000/uL increase in platelets

Blood Products

Product	Uses/Effect
Red Blood Cells (1 unit= About 350 mL)	1 unit increases: Hematocrit by 3 percentage points Hemoglobin by 1 g/dL
Fresh Frozen Plasma (1 unit = 200 to 300 mL)	1 unit FFP increases fibrinogen by 7 to 10 mg/dL
Cryoprecipitate (1 unit= 10 to 20 mL, dose is 2 bags of 5 pooled units/ bag) 100-200 ml total	1 unit -Increases plasma fibrinogen by about 45 mg/dL
Adult Standard Platelets (1 unit= 200 to 300 mL)	1 Adult standard dose of platelets raises platelet count by about 30,000/microL



HANDLE: Typical MTP pack



MTP Products



Disseminated intravascular Coagulation:

Thrombohemorrhagic disorder with concurrent activation of the coagulation and fibrinolytic pathways, resulting in simultaneous fibrin clot formation and lysis

Debrief


Important but often missed following an untoward event

- What went well
- Opportunities
- Barriers
- System issues
- Action Items: based on lessons learned to alter the plan next time
- Risk Management?



Complications of PPH

- Blood Component transfusion reactions/complications
- Acute Renal Injury/kidney failure
- Anemia
- Fluid overload (pulmonary edema, dilutional coagulopathy)
- Sepsis
- Sherman's Syndrome (intrauterine scaring/adhesions)
- Infertility
- PTSD
- Death



Knowledge check

The 4 "T's of PPH are:

- A. Trauma
- B. Toxins
- C. Torsion
- D. Tissue
- E. Tears
- F. Thrombin
- G. Tone



Knowledge Check

The normal blood flow through the placental site each minute is 600-800 mls per minute.

A. True

B. False

References

American College of Obstetricians and Gynecologists. (2006). ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists, Number 76. Postpartum Hemorrhage

AWHONN (2014). Quantification of blood loss: AWHONN Practice Brief Number 1

Belfort, M. (2023) Overview of postpartum Hemorrhage. UpToDate

Birch, L., Jones, N., Doyle, P. M., Green, P., Mclaughlin, A., Champney, C.,... Taylor, K. (2007). Obstetric skills drills: evaluation of teaching methods. Nurse education today, 27(8), 915-922.

California Maternal Quality Care Collaborative (2022). OB Hemorrhage toolkit

Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol 2017; 130:e168.

CMQCC (2015). Cumulative Quantitative Assessment of Blood Loss version 2.0

Council on Patient Safety (2019). Obstetric Hemorrhage (+AIM). <u>https://safehealthcareforeverywoman.org/patient-safety-bundles/obstetric-hemorrhage/</u>

Devine, P.C. (2009). Obstetric hemorrhage. Semin perinatol, 33, 76-81.

Friedman, A.M., Campbell, M.L., Kline, C.R., Wiesner, S., D'Alton, L.E. & Shields, L. E. (2018). Implementing obstetric early warning systems. American Journal of Perinatology, 8, e79-84

Jeffries, p. R., Bambini, D., Hensel, D., Moorman, M., & Washburn, J. (2009). Constructing maternal-child learning experiences using clinical simulations. JOGNN: journal of obstetric, gynecologic & neonatal nursing, 38(5), 613-623.

Joint Commission (2019). R³ Report. Requirement, Rationale, Reference. Provision of care, treatment and service standards for maternal safety. Issue 24.

Joint commission on accreditation of healthcare organizations. (2010). Preventing maternal death. (Sentinel event alert issue #44).

Main, E. Et al. National Partnership on Maternal Safety- Concensus bundle on obstetric hemorrhage

Main, E.K., McCain, C.L., Morton, C.H., Hotlby, S & Lawton, E.S. (2015). Pregnancy-related mortality in California: Causes, characteristics and improvement opportunities. *Obstetrics and Gynecology*, 125. 938-47

Lagrew D, McNulty J, Sakowski C, Cape V, McCormick E, Morton CH (2022). Improving Health Care Response to Obstetric Hemorrhage, a California Maternal Quality Care Collaborative Toolkit, 2022.

Oyelese, y. & Ananth, C.V. (2010). Postpartum hemorrhage: epidemiology, risk factors, and causes. Obstet gynecol, 53(1), 147-156.

Robertson, B., Schumacher, L., Gosman, G., Kanfer, R., Kelley, M., & Devita, M. (2009). Simulation-based crisis team training for multidisciplinary obstetric providers. Simulation in healthcare: the journal of the society for simulation in healthcare, 4 (2), 77-83.

Shields. L.E., Wiesner, S., Klein, C.,, Pelletreau, B. & Hedriana, H.L. (2016) Use of maternal early warning trigger tool reduces maternal morbidity. Journal of Obstetrics and Gynecology

WOMAN Trial Collaborators (2017). Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum hemorrhage (WOMAN): an international, randomized, double-blind, placebo-controlled trial. Lancet

World Health Organization (WHO): Department of making pregnancy safer. (2009). WHO recommendations for the prevention of postpartum hemorrhage.

Shoulder Dystocia

OBSTETRICAL EMERGENCIES



Objectives

- Identify known and recognize limitations of risk factors for shoulder dystocia
- Standardize the team approach to this emergency
 - What to do
 - What not to do
- Know the important information to be recorded in the medical record after a shoulder dystocia

Definition

Definition : Shoulder dystocia is defined as failure of the shoulders to spontaneously traverse the pelvis after delivery of the fetal head.

"A delivery that requires additional obstetric maneuvers following failure of gentle downward traction on the fetal head to effect delivery of the shoulders"

Shoulders enter the pelvis in an anteriorposterior position rather than oblique

- Anterior shoulder is behind the public bone
- Fetal brachial plexus nerves stretch



ACOG Practice bulletin 2002 (reaffirmed in 2013) definition of "shoulder dystocia"

Risk Factors

- TRUTH: Shoulder Dystocia cannot be accurately predicted or prevented
- Although many cases are unanticipated, we can heighten our readiness and response
 - Promptly recognize when gentle traction alone is inadequate for delivery
 - Proceed through an orderly sequence of maneuvers



Risk Factors

- Birth weight: > 4000gm
- Diabetes
- Previous SD- recurrence 10%
- Maternal Obesity, increased weight gain
- Abnormal progress of labor
- Post term
- OVD

Incidence of shoulder dystocia by birth weight in pregnancies with and without maternal diabetes

Birth weight (g)	Shoulder dystocia in nondiabetic pregnancies (%)	Shoulder dystocia in diabetic pregnancies (%)
Less than 4000	0.1 to 1.1	0.6 to 3.7
4000 to 4499	1.1 to 10.0	4.9 to 23.1
4500 or more	2.7 to 22.6	20.0 to 50.0



Delivery Decision? Shared Decision Making

- Planned Cesarean?
 - Hx of prior SD with
 - Hx of severe neonatal injury
 - EFW > 4500 (diabetes- 15% risk) or 5000 grams (w/o diabetes- < 20% risk)
- Trial of labor?
 - Multip w/o hx of difficult birth
 - Spontaneous labor at 39 weeks
 - EFW < 4000gm
- Prolonged Second stage and > EFW

At least 50 percent of pregnancies complicated by shoulder dystocia have no identifiable risk factors and most risk factors are weakly predictive of morbidity from shoulder dystocia

Response

Quick Identification

• Call for help

Prompt Interventions:

- DISCOURAGE PUSHING- Coach breathing
- Maneuvers
 - McRoberts --tilts the pelvis
 - Suprapubic Pressure- External rotation
 - **Posterior arm-** sweeps posterior arm across chest to rotate anterior shoulder backward
 - Rubin-adducts shoulders
 - Wood's screw-rotates shoulders anteriorly
 - Gaskin –all fours
 - Zavenelli







NO PUSHING & NO PROVIDER DOWNWARD GUIDANCE UNTIL DYSTOCIA IS RESOLVED ACOG Practice Bulletin 178 May 2017





Documentation

- Delivery of head
- Delivery of Shoulders
- Sequence of maneuvers
- Pushing discouraged
- No fundal Pressure
- All staff present
 - The team called and when they arrived
 - NICU/Neo/RT
 - Hospitalist
 - Anesthesia
 - Additional Help (supervisor)
- FHR



Documentation Management after the Delivery

Obtain Cord gases

Inform pediatric provider

Document fully

Discuss with parents

Documentation debrief

- Maternal complications
 - Cervical/vaginal/perineal lacerations
 - Hematoma
 - Separation of symphysis
 - PPH
 - Endometritis
 - Birth trauma
- Newborn exam
 - Fracture of clavicle/humerus
 - Disruption/evulsion of nerve roots
 - Increased intracranial pressure

Knowledge Check

What part of the baby is given suprapubic pressure?

- A. Anterior aspect of posterior arm
- B. Anterior aspect of anterior arm
- C. Posterior aspect of anterior arm
- D. Posterior aspect of posterior arm
- E. Clavical

Knowledge Check

• How many shoulder dystocia cases are not predicted

A. 30%

B. 40%

C. 50 %

D. 60%

E. Who Knows?



References

ACOG Practice Bulletin, Shoulder Dystocia, Number 40, (2014)

ACOG, Neonatal brachial plexus palsy task force report (July 2013)

<u>Committee on Practice Bulletins—Obstetrics. Practice Bulletin No 178: Shoulder Dystocia. Obstet Gynecol 2017; 129:e123. Reaffirmed</u> 2019.

Joint Commission on Accreditation of Healthcare Organizations. <u>www.jcaho.org</u>

Rodis, J.F. (2023). Shoulder dystocia: Intrapartum diagnosis, management and outcome

Barbieri, R.(2013), The natural history of obstetric brachial plexus injury. *OBG Management* Clark et al.(2008) Reducing Obstetric Litigation Through Alterations in Practice Patterns. *Obstetrics & Gynecology, 6*, 112

Grobman, W., Hornbogen, A., Burke, C., Costello, R.(2010) Development and implementation of a team-centered shoulder dystocia protocol. Simulation in Healthcare, Hoffman et al.(2011) A comparison of obstetric maneuvers for the acute management of shoulder dystocia, *Obstetrics & Gynecology*, 117, 6

Sepsis

OBSTETRICAL EMERGENCIES



Objectives

- Recognize rational for including the OB population into standard sepsis quality improvement work
- Name three sepsis considerations that are unique to perinatal population




QUESTION

How many of you have adopted OB Sepsis protocol at your organization?



Did you know?

- Maternal sepsis causes at least 261,000 maternal deaths every year worldwide.
- A recent analysis found that 23% of all maternal deaths in the U.S. are related to sepsis.
- According the CDC, 14.3% pregnancy related deaths between 2017-2019 were due to infection/sepsis.
- Infection/sepsis is the 2nd leading cause of pregnancy related death
- Black women have more than twice the risk of severe maternal sepsis as compared to their white counterparts



Did you know?

- Maternal sepsis causes at least 261,000 maternal deaths every year worldwide.
- A recent analysis found that 23% of all maternal deaths in the U.S. are related to sepsis.
- According the CDC, 12.5% pregnancy related deaths between 2011-2018 were due to infection/sepsis.
- Infection/sepsis is the 2nd leading cause of pregnancy related death
- Black women have more than twice the risk of severe maternal sepsis as compared to their white counterparts




Increasing Trend

- Advancing maternal age Obesity
- Diabetes
- Cesarean Birth
- ART
- Multiple Gestation
- Long labor



Pathogens and Sources




Intraamniotic Infection(Chorioamnionitis)

Most common

- 3.9% all births
- 40-70% PTB due to PTL; PPROM

Risk Factors:

- Length of labor
- Duration of rupture of membranes
- Multiple cervical exams
- Internal monitoring/procedures
- GBS
- STI
- Mec
- Previous IAI
- Alcohol/Tobacco use



Presentation - Dx is usually made on clinical findings alone

- Fever (100%)
 - ≥39 x1
 - 38-38.9 on 2 more measurements 30 minutes apart

PLUS one or more:

- Elevated WBC > 15,000(70-90%)
- Birthing Patient Tachycardia >100/min (50-80%)
- Fetal Tachycardia > 160/min (40-70%)
- Decreased FHR variability
- Uterine tenderness(4-25%)
- Bacteremia(5-10%)
- Purulent or malodorous amniotic fluid



PLACENTA TO PATHOLOGY! Confirmation: Evidence of infection and/or inflammation in placenta, membranes, or umbilical cord. Amniotic fluid- positive gram stain, low glucose level, positive culture, high WBC count

Chorio key points

- Give Antibiotics
- Give Tylenol
- Deliver-does not necessarily indicate C/S Birth
- Increased risk for:
 - Dysfunctional labor
 - Cesarean birth
 - Uterine atony
 - PPH
 - Blood transfusion
 - Localized PP infection
 - Sepsis

← Chorioamnionitis / Intraamniotic Infection Treatment
Chorioamnionitis / Intraamniotic Infection Treatment
O Patient tolerates penicillins
ampicillin (OMNIPEN) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g, Intravenous, Administer over 30 Minutes, Every 6 hours scheduled, Include Now, For 8 doses Reason: Empiric Select Indication (known or suspected): Other Describe "Other" Indication: Chorioamnionitis
© And
gentamicin (GARAMYCIN) 252 mg in sodium chloride 0.9 % 100 mL IVPB 252 mg (rounded from 253 mg = 5 mg/kg × 50.6 kg Ideal weight), Intravenous, Administer over 30 Minutes, Every 24 hours, First dose today at 1315, For 2 doses Reason: Empiric Select Indication (known or suspected): Other Describe "Other" Indication: Chorioamnionitis Will patient be on therapy for greater than 48 hours? No



What's Unique about Maternal Sepsis

- Uncommon
- Typically Young & Healthy
- Limited studies
- Challenges to identification
- SIRS Criteria
- Scoring tool(s):
- NOT validated for the prestant population





Unique OB Physiology

• Normal OB physiology mimics SIRS:

- WBC higher
- HR increases
- RR Increases

• Effect of Labor

- HR, RR: pain and pushing
- Temp: dehydration, epidural
- Hypotension with epidural
- Altered mental status

Postpartum

• Fatigue




SEPSIS Definition: The presence of 2 or more SIRS criteria with a presumed or

confirmed infectious process

t Screening Criteria	OB Population
p > 38°C (100.4°F) or < 36°C (96.8°F)	Temp > 38°C (100.4°F) or < 36°C (96.8°F)
90	HR >110
20	WBC > 14,000 or < 4,000 or
C >12,000, < 4,000 or >10% Bands	> 10 % bands
ental status change	Subtle changes in mental status
slucose > 140 mg/dl in the absence of diabetes	•Blood glucose > 140 mg/dl in absence of diabetes
	o > 38°C (100.4°F) or < 36°C (96.8°F) 90 20 2 >12,000, < 4,000 or >10% Bands ental status change



Maternal Sepsis Standard Work



Maternal Sepsis Standard Work

			Apply Patient Label Here	
	CODE SEPS	SIS CHECKLIST		
	Inpatient OB Un	<u>it</u> Early Recognition		
Date:		*TIME ZERO		
Patient's	Room Number:	*Time Zero Inpatient: Any two of signs iden confirms suspicion for infection	tified + Attending	
	Any two SIRS symptoms below	AND Suspected infection?		
<u>tecommended</u> Best Practices	HR>110 Temp < 36 OR betwee RR>20 3B-38 9 ⁵ C SBP<90 WBC > 11 OR <4 FHR >*60 Acute Change in Mental Status	en Yes • 1. Call Rapid Response Team for immediate assessment an 2. RRT initiates Sepsis NiO (n	d orders	
친 집	Any isolated Temp of 39 ⁰ Notify f	MD Not Continue to monitor patient		
		completed in ONE HOUR (from TIME ZERO)		
		or, RRT RN to facilitate implementation as	Result/Time/Initial	
_	applicable = Call Lab stat to draw		Draw Time(set 1)	
1	Lactate level stat		Draw Time set 2	
2	 Blood Cultures x 2 stat 		<u> </u>	
-		ntibiotics if unsuccessful with blood draw)		
	 NS or LR Bolus 500mL (wide oper 			
	Primary RN Recheck VS every 15 min MAP < 65.	ns x 2 from completion of bolus. If S8P <90 or		
		ry 1 hour x2; if patient deteriorates, cali ART		
	and provider for further directions).			
		r bolus, start discussion with provider about		
	CCU administen and further fluid bolu CCU administence of the from MD		1	
3	 Antibiotic start time: 	 start by nobilit from time zero ;]	
		and obtain verbal order for repeat lactate	1	
	and further fluid bolus			
		completed by HOUR 3 (from TIME ZERO)	1	
4	C NS or LR 30mL/kg Fluid Bolus. (If Total calculated volume to infuse imit		Time completed: Tota: given:	
		completed by HOUR 4 (from TIME ZERO)	T	
5	Repeat Lactate 4 hours after	first, if first lactate is ⊳z		
<u> </u>	•	_(Date) at(Time)	Draw Time:	
	(Lactate level-Critical Value = 14 0) M			
	Consider Was on retrort of with some	ns hunotaaska offer 20mi /kg bolus	Result: Time	
6	Consider Vasopressors if with remain	ns hypotensive after somL/kg bolus. sment after completion of 30mL/kg bolus OR	Fund resuscitation	
	 Page MOTOL Huid Status reasses: 4 hours of time zero. 	where when completion or some kg bolds Ok	(Start time)	
	(MD reassessment required 4 hours a	after start of fluid resuscitation)	Time MD page	
7				

- ✓ Lactate Level
- ✓ Blood Cultures x2
- ✓ LR Bolus 500cc
- ✓ IV Antibiotics

IMPLEMENT THE BUNDLES...Goal within 1 hour

In the setting of Septic shock LR 30ml/kg Fluid Bolus to be completed by 3hours

MD assessment for fluid status reassessment after completion of 30ml/kg bolus 4hour of time zero * This is a core measure

Story.... Before OB SEPSIS PROTOCOL

Postpartum Day 1: Primip OVD

Reported feeling "very tired", pain well controlled with current meds, ambulating well, tolerating reg diet. Baby doing well, BF well

WBC 16.4 T 36.2 BP 118/71 Pulse 115 RR: 18

3 Hours Later:

Pain 9/10 **not** well controlled with current medications: Crying from exhaustion and pain, limited coping mechanisms. C/O Cramping stiches, hemorrhoids. Developed chest pain, right shoulder pain, SOB, N/V, dizziness

T: 38.7 HR: 120-156 BP: 95/45- 76/34 RR: 40-47 WBC=*1.7 repeat 1.6

Mother comments that this is not her typical response to pain or stress

Rapid Response Team:

CT Scan, Pulmonary angiogram, Abdominal Ultrasound

Transferred to Critical Care Unit:

BP: 68/40 P:155-160 Sa02 87% on 6L Lactate 4.8

- CT Angiogram- No PE
- Sepsis protocol initiated
- IV antibiotics (Unasyn, Clindamycin, Vancomycin)
- Fluid Volume Resuscitation
- Vasopressor Support
- 02 requirement up to 45L/min
- Respiratory failure, increasing pulmonary edema/pleural effusions. Intubated for respiratory support
- Decreased Urine output

Major Goals of sepsis management were met: She was treated emergently with fluid resuscitation, antibiotic administration....

What else?

Postpartum Day 3:

To OR for Surgery: TAH, APPY, and Abdominal washout. Uterus was "mushy" and tissue friable

- **4** liters of purulent Ascites
- Positive for GAS
- Remained ventilated 9 days (ARDS)

Postpartum Day18: Discharged Home T: 36.5, BP: 127/75 P: 88 RR: 16 Sao2 100%





Knowledge Check

A fever is necessary in the diagnosis of sepsis in the OB population?

A. True

B. False



Knowledge check

How quickly should the 30ml/kg fluid bolus be administered?

- A. Within your shift
- B. 3 hours
- C. 6 hours
- D. Until the patient is normotensive

References

ACOG (2022). Committee Opinion <u>No. 712: Intrapartum Management of Intraamniotic Infection. Obstet</u> <u>Gynecol 2017; 130:e95. Reaffirmed 2022.</u>

Anderson, B.L. (2014). Puerperal Group A Streptococcal Infection: Beyond Semmelweis. *Obstetrics & Gynecology, 123*.

Barton & Sibai (2012). Severe sepsis and septic shock in pregnancy. *Obstet Gynecol*. 120:689-706.

Chen, K.T. (2023) Postpartum endometritis. Up-to-date.

CMQCC (2022). Improving diagnosis and treatment of maternal sepsis

Knowles, S.J.,O'Sullivan, N.P., Meenan, A.M., Hanniffy, R., Robson, M. (2014). Maternal Sepsis incidence, etiology and outcome for mother and fetus: a prospective study. *Royal College of Obstetrics and Gynecologists*. DOI: 10, 1111/1471-0528.12892.

Kumar, A. (2006). Duration of Hypotension Prior to Initiation of Antimicrobial Therapy. *Crit Care Med*, 34, 1589-96

Neligan, P.J. & Laffey, J. (2011). Clinical review: Special populations-critical illness and pregnancy. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012, 3rd Ed publication (CCM, 2013; 41(2):580-637)

Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Plante LA, Pacheco LD, Louis JM. SMFM Consult Series #47: Sepsis during pregnancy and the puerperium. Am J Obstet Gynecol 2019; 220:B2.

Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012, 3rd Ed publication (CCM, 2013; 41(2):580-637)

Thevenet, A. (2023). Intraminiotic infection (Clinical Chorioamnionitis). UpToDate